Can Visa Solve the High Remittance Fees Problem With Stablecoins? — Neutral
V Zacks Investment Research — June 17, 2025V taps stablecoin tech and fintech partnerships to cut digital remittance costs and boost security.
Astera Labs Soars on Expanding AI Reach With Alchip, NVIDIA Deals — Positive
ALAB Zacks Investment Research — June 17, 2025Astera Labs teams up with Alchip and deepens NVIDIA ties as surging AI demand fuels 144% revenue growth in Q1 2025.
BlackRock Rides on Private Market Growth: Is Now the Time to Buy BLK? — Positive
BLK Zacks Investment Research — June 17, 2025Last week, BlackRock Inc. BLK unveiled its plans to expand in private markets during an Investor Day conference. The company is targeting $400 billion in private markets fundraising by 2030, as it predicts that the private credit market could expand to $4.5 trillion in 2030 from $1.6 trillion last year.
Box (BOX) Just Flashed Golden Cross Signal: Do You Buy? — Positive
BOX Zacks Investment Research — June 17, 2025After reaching an important support level, Box, Inc. (BOX) could be a good stock pick from a technical perspective. BOX recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
After Golden Cross, Diversified Healthcare (DHC)'s Technical Outlook is Bright — Positive
DHC Zacks Investment Research — June 17, 2025After reaching an important support level, Diversified Healthcare Trust (DHC) could be a good stock pick from a technical perspective. DHC recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Jabil Inc. (NYSE:JBL ) Q3 2025 Earnings Conference Call June 17, 2025 8:30 AM ET Company Participants Adam E. Berry - Senior Vice President of Investor Relations & Communications Gregory B.
IQQQ offers high income (15.66% yield) by tracking the Nasdaq 100 with a daily covered call strategy, balancing income and tech exposure. Top holdings—Microsoft, Nvidia, and Apple—are leaders in AI and innovation, driving long-term growth potential for the fund. Covered call strategy provides steady income and downside cushion, but caps upside in strong bull markets; careful management is crucial.
VIG focuses on dividend growth and quality large caps, offering stability and a growth tilt, but with a lower yield than peers with a focus on current yield. VIG outperforms in bull markets, led by large-cap tech and quality growth stocks, while current yield-focused ETFs lead when value and cyclical sectors rally. Top holdings in VIG are stable, growth-oriented names with well-managed concentration risk, making them resilient in volatile markets but less defensive in deep downturns.
Here's Why Check Point Software (CHKP) is a Strong Growth Stock — Positive
CHKP Zacks Investment Research — June 17, 2025Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why EQT Corporation (EQT) is a Top Growth Stock for the Long-Term — Positive
EQT Zacks Investment Research — June 17, 2025Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Flowserve (FLS) is a Strong Growth Stock — Positive
FLS Zacks Investment Research — June 17, 2025Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why McKesson (MCK) is a Top Growth Stock for the Long-Term — Positive
MCK Zacks Investment Research — June 17, 2025Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Will Macroeconomic Headwinds Derail CAVA's Traffic Gains? — Negative
CAVA Zacks Investment Research — June 17, 2025CAVA grows traffic 7.5% in the first quarter despite economic pressures, holding guidance steady and resisting price hikes to stay competitive.
JPM Files Digital Asset Trademark: Set to Ride on Stablecoin Traction? — Neutral
JPM Zacks Investment Research — June 17, 2025JPMorgan files for "JPMD" trademark, signaling deeper digital asset ambitions as interest in stablecoins intensifies.
Here's Why Paypal (PYPL) is a Strong Momentum Stock — Positive
PYPL Zacks Investment Research — June 17, 2025The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Standard Motor Products (SMP) is a Strong Momentum Stock — Positive
SMP Zacks Investment Research — June 17, 2025Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why UGI (UGI) is a Strong Momentum Stock — Positive
UGI Zacks Investment Research — June 17, 2025Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why GSK (GSK) is a Strong Momentum Stock — Positive
GSK Zacks Investment Research — June 17, 2025Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GILD ALERT: Ongoing Investigation Into Gilead Sciences, Inc. - Contact Levi & Korsinsky — Neutral
GILD Accesswire — June 17, 2025NEW YORK, NY / ACCESS Newswire / June 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gilead Sciences, Inc. ("Gilead Sciences, Inc.") (NASDAQ:GILD) concerning possible violations of federal securities laws. Gilead issued a press release on June 10, 2025, announcing that "[t]he U.S. Food and Drug Administration has placed a clinical hold on Gilead's HIV treatment trials of GS-1720 (an investigational integrase strand transfer inhibitor) and/or GS-4182 (an investigational capsid inhibitor)[,]" specifying that "[t]he clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte …
As my portfolio's fourth-biggest position, Realty Income remains a core holding for me. The company is leaning into a huge growth runway overseas to fuel continued AFFO per share growth for shareholders. Realty Income has recently flexed its financial muscles.
